Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study
29/04/2026 16:55
April 29 (Reuters) - Newron Pharmaceuticals SpA NWRN.S: NEWRON REPORTS A PAUSE OF ENROLLMENT OF NEW STUDY PARTICIPANTS IN US CENTERS OF ENIGMA-TRS 2 STUDY NEWRON PHARMACEUTICALS SPA: PAUSE OF ENROLLMENT LIMITED TO US SITES IN ENIGMA-TRS 2; GLOBAL ENIGMA-TRS 1 NEWRON PHARMACEUTICALS: FDA ACTION TO PAUSE ENROLLMENT FOLLOWS CO'S NOTIFICATION TO FDA OF DEATH OF PARTICIPANT AT CLINICAL SITE OUTSIDE US Source text: ID:nBw2MMqMra Further company coverage: NWRN.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study